Bioassay & Analytics for Biologics & ADCs

In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. 

Access our corporate brochure to learn why we are considered to be the leading bioconjugate, antibody-drug conjugate (ADC), and complex biologics CDMO + CRO.

New facility will be research partnering company’s sixth global site and will be dedicated to mammalian biologics

Abzena’s ThioBridge™ Antibody-Drug Conjugation (ADC) platform is a solution that leverages 20+ years of our experience to improve stability, potency, & efficacy

At Abzena, our focus is on providing a de-risked and streamlined development pathway for our customers. As the leading CDMO + CRO for complex biologics and bioconjugates and ADCs, we support customers with fully integrated programs or individual tailored services that span from early-stage research and discovery through commercial launch to ensure that your program progresses smoothly through the critical path and rapidly advances to its next milestone.